These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 12581195

  • 1. Rebound hepatosplenomegaly in type 1 Gaucher disease.
    Tóth J, Erdos M, Maródi L.
    Eur J Haematol; 2003 Feb; 70(2):125-8. PubMed ID: 12581195
    [Abstract] [Full Text] [Related]

  • 2. Improvement of splenomegaly and pancytopenia by enzyme replacement therapy against type 1 Gaucher disease: a report of sibling cases.
    Tsuboi K, Iida S, Kato M, Hayami Y, Hanamura I, Miura K, Harada S, Komatsu H, Banno S, Wakita A, Nitta M, Ueda R.
    Int J Hematol; 2001 Apr; 73(3):356-62. PubMed ID: 11345203
    [Abstract] [Full Text] [Related]

  • 3. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 4. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months.
    Pastores GM, Sibille AR, Grabowski GA.
    Blood; 1993 Jul 15; 82(2):408-16. PubMed ID: 8392397
    [Abstract] [Full Text] [Related]

  • 5. Enzyme replacement therapy in type I Gaucher disease.
    Kay AC, Saven A, Garver P, Thurston DW, Rosenbloom BF, Beutler E.
    Trans Assoc Am Physicians; 1991 Jul 15; 104():258-64. PubMed ID: 1845151
    [No Abstract] [Full Text] [Related]

  • 6. Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1.
    Cerón-Rodríguez M, Barajas-Colón E, Ramírez-Devars L, Gutiérrez-Camacho C, Salgado-Loza JL.
    Mol Genet Genomic Med; 2018 Jan 15; 6(1):27-34. PubMed ID: 29471591
    [Abstract] [Full Text] [Related]

  • 7. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.
    Burrow TA, Cohen MB, Bokulic R, Deutsch G, Choudhary A, Falcone RA, Grabowski GA.
    J Pediatr; 2007 Feb 15; 150(2):202-6. PubMed ID: 17236903
    [Abstract] [Full Text] [Related]

  • 8. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, Zimmermann A.
    J Inherit Metab Dis; 2007 Oct 15; 30(5):783-9. PubMed ID: 17703370
    [Abstract] [Full Text] [Related]

  • 9. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
    Lukina E, Watman N, Dragosky M, Lau H, Avila Arreguin E, Rosenbaum H, Zimran A, Foster MC, Gaemers SJM, Peterschmitt MJ.
    Am J Hematol; 2019 Jan 15; 94(1):29-38. PubMed ID: 30264864
    [Abstract] [Full Text] [Related]

  • 10. Enzyme augmentation in moderate to life-threatening Gaucher disease.
    Fallet S, Grace ME, Sibille A, Mendelson DS, Shapiro RS, Hermann G, Grabowski GA.
    Pediatr Res; 1992 May 15; 31(5):496-502. PubMed ID: 1603627
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease.
    Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, van Oers MH.
    Am J Med; 1997 Sep 15; 103(3):185-91. PubMed ID: 9316550
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic goals in Gaucher disease.
    Mistry P, Germain DP.
    Rev Med Interne; 2006 Mar 15; 27 Suppl 1():S30-8. PubMed ID: 16644400
    [Abstract] [Full Text] [Related]

  • 13. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 15; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 14. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI, Giraldo P, Giralt M.
    Sangre (Barc); 1997 Jun 15; 42(3):189-94. PubMed ID: 9381260
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A.
    Am J Med; 2002 Aug 01; 113(2):112-9. PubMed ID: 12133749
    [Abstract] [Full Text] [Related]

  • 16. [Gaucher disease--one of the possible causes of splenomegaly--case report].
    Sokołowska B, Skomra D, Czartoryska B, Tomczak W, Tylki-Szymańska A, Repelewska M, Drop A, Gromek T.
    Pol Arch Med Wewn; 2004 Sep 01; 112(3):1107-12. PubMed ID: 15727093
    [Abstract] [Full Text] [Related]

  • 17. [Therapeutic targets in Gaucher's disease].
    Giraldo P, Roca M.
    Med Clin (Barc); 2011 Sep 01; 137 Suppl 1():46-9. PubMed ID: 22230126
    [Abstract] [Full Text] [Related]

  • 18. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients.
    Poll LW, Koch JA, Willers R, Aerts H, Scherer A, Häussinger D, Mödder U, vom Dahl S.
    Blood Cells Mol Dis; 2002 Sep 01; 28(2):209-20. PubMed ID: 12064917
    [Abstract] [Full Text] [Related]

  • 19. Treatment of Gaucher's disease with OGT 918.
    Mistry PK.
    Lancet; 2000 Aug 19; 356(9230):676-7. PubMed ID: 10968454
    [No Abstract] [Full Text] [Related]

  • 20. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy.
    Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI.
    Blood Cells Mol Dis; 2002 Aug 19; 28(2):288-96. PubMed ID: 12064924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.